ACADIA Pharmaceuticals Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while Booz Allen Hamilton Holding Corporation trades at $78.3 (market cap $9.45B). The key difference: Booz Allen Hamilton Holding Corporation is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BAH | |
|---|---|---|
Market Cap | $5.07B | $9.45B |
Sector | Health | Industrials |
52-Week High | $29.41 | $111.63 |
52-Week Low | $20.06 | $59.71 |
Enterprise Value | $4.19B | $13.07B |
Dividend Yield | — | 3% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →